

# VALIDATION OF A SCALE OF ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILIA

Torres-Ortuño Ana<sup>1</sup>, Cuesta-Barriuso Rubén<sup>2,3,4</sup>, Nieto-Munuera Joaquín<sup>1</sup>, López-Pina José Antonio<sup>5</sup>, Moreno-Moreno Manuel<sup>3</sup>

<sup>1</sup>Department of Psychiatry and Social Psychology. Faculty of Medicine, University of Murcia. Spain. <sup>2</sup>Department of Physiotherapy, School of Biomedical and Health Sciences, European University of Madrid, Spain.

<sup>3</sup>Real Fundación Victoria Eugenia, Madrid, Spain. <sup>4</sup>Federación Española de Hemofilia-Fedhemo, Madrid, Spain. <sup>5</sup>Department of Basic Psychology and Methodology. Faculty of Psychology, University of Murcia. Spain

## Introduction and Objectives

Adherence is a complex and broad term. It involves not only taking medication but changes in habits, lifestyles and active participation in prescribed treatment for a disease. In hemophilia there are VERITAS-Pro and VERITAS-PRN but only focused on compliance. Our vision of adherence includes other factors besides compliance. The aim is to validate a new scale of adherence to PWH consisting of five dimensions: Disease Awareness (CE), Knowledge of the Sequelae (CS), Difficulties Treatment (DT), Doctor-Patient Relationship (RMP), and Bleeding Treatment Processes (TP), plus and Knowledge of the Disease. Psychometric analysis of the scale adherence

## Material and Methods

We developed a total of 126 items for the five dimensions, plus 10 items for the dimension of knowledge of the Disease (a likert rating scale 0 to 4). The scale was sent to five external experts (who care PWH and 15 years of experience) for assessment the relevance of each item in each dimension. After, the scale was administered to 10 PWH of different ages to examine the level of understanding and clarity of the items and if these strategies accounted adherence to the disease.

## Results and Conclusion

The interjudge agreement was between .90 and 1.00. Depending on the opinion of the judges and the opinion of the patients interviewed, 65 items were removed. The scale will be administered in the pilot consists of 61 items (CE: 16 items; CS: 6 items; DT: 20 items; RMP: 7 items; and TP 12 items), plus the 10 Knowledge of Disease.

Adherence is a multidimensional concept and should not only be measured by compliance with treatment but also is affected by psychosocial factors of patients and professionals. We believe this new scale adherence provide a more comprehensive view of the determinants of adherence PWH.

## REFERENCES

- Duncan NA, Kronenberger W, Roberson C, Shapiro A. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. *Haemophilia*, 2009; 16: 47-53.
- Duncan NA, Kronenberger W, Roberson C, Shapiro A. VERITAS-PRO: a new measure of adherence to prophylactic regimens in haemophilia. *Haemophilia*, 2010; 16: 247-255.
- Nogues Solan X, Sorli Redo ML, Villar Garcia J. Instrumentos de medida de adherencia al tratamiento. *An Med Internal (Madrid)*; 24:138-141.
- Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. *Haemophilia*, 2013; 19(1): 35-43
- World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization, 2009

